Teligent Inc., a Buena-based specialty generic pharmaceutical company, announced it has made some changes to its leadership.
Jason Grenfell-Gardner, CEO, president and member of the board if directors, is stepping down from his roles while Tim Sawyer will be taking over as CEO and president, both effective immediately.
“Mr. Grenfell-Gardner and the board of directors have mutually agreed that now is the right time to transition the leadership of the company. The company thanks Mr. Grenfell-Gardner for service over the past seven and a half years and wishes him success in his future endeavors,” the company said in a news release.
Sawyer, who spend 16 years at Barr Laboratories, most recently served as its executive vice president, global generic sales and marketing. After Barr, he served as the senior vice president, corporate strategic development at Mylan. He also has experience working in private equity backed companies in the generic and OTC sectors.
Sawyer will be responsible for achieving the company’s main missions and goals, including resolving a warning letter from the U.S. Food and Drug Administration from 2019, pass a prior approval inspection, launch its first manufactured injectable product out of its facility in Buena, and more.
“I am excited to join Teligent and look forward to working with the team to drive execution, launch new products out of the Buena facility and accelerate Company performance,” Sawyer said.
